Benzinga’s News Roundup (LXRX, MET, AZN, BA)

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) reported today that it would sell $95 million of common stock in an underwritten public offering. Lexicon also intends to grant underwriters a 30-day option to purchase up to an additional $14.25 million of common stock to cover over-allotments. LXRX decreased 1.69% to $1.75 in the pre-market session. The 52-week trading range for LXRX is $0.89 - $3.78. LXRX has increased 17% in the last six months.

MetLife, Inc. (NYSE: MET) announced today a definitive agreement to acquire one of American International Group, Inc.`s (AIG) international subsidiaries, American Life Insurance Company (ALICO), for approximately $15.5 billion. MetLife increased 2.75% to $39.99 in the pre-market session. The 52 week trading range for MET is $11.37 -$41.45. MET closed at $38.92 in the last trading session.

AstraZeneca plc (ADR) (NYSE: AZN) announced today the top-line results of a Phase II/III study evaluating RECENTIN compared with Avastin in patients with first-line metastatic colorectal cancer. AstraZeneca decreased 1.78% to $44.65 in the pre-market session. The 52-week trading range for AZN is $29.96 - $50.70. AZN has surged over 48% in the last year.

The Boeing Company (NYSE: BA), along with Turkish Airlines announced today that they have finalized an order for 20 model 737 airplanes valued at $1.6 billion at current list prices. The order includes 10 737-800s and 10 737-900ER (Extended Range) airplanes. The 737-900ER will be the latest 737 family member to join the Turkish Airlines fleet. The Boeing Company increased 0.25% to $68.10 in the pre-market session. BA closed at $67.93 in the previous trading session. BA has surged over 38% in the last six months.